ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

New CCOP RFA Available; Briefing At ASCO Jammed

June 2, 1989

Survivors With Gene Variant At More Risk For Heart Disease

June 25, 2010

National Cancer Policy Board will end in 2005, NCI to support a cancer forum at IOM.

November 5, 2004

Ultrasound Shown to be Superior Diagnostic Compared to Mammography in Women Ages 30-39

October 26, 2012

Guidelines Adopted For Pathology Review

February 22, 1980

Martha Fewell, Assistant To NCI Directors, To Retire

May 3, 2002